With the continuous advancement and widespread application of detection assays for myelin oligodendrocyte glycoprotein (MOG) antibodies, MOG antibodies (MOG-Abs) are increasingly being identified in a broadened spectrum of acquired demyelinating disorders. The gene discussed is MOG; the disease is demyelinating disease.